University of Colorado, Denver
The goal of this clinical trial is to learn how atorvastatin in patients with advanced high grade serous cancer of the ovary, fallopian tube, or peritoneum changes the tumor immune environment. The main question it aims to answer is: * Does atorvastatin combined with standard of care chemotherapy and surgery changes the number of tumor-promoting macrophages in the tumor microenvironment * Researchers will compare standard of care chemotherapy and surgery to see if there is a difference in tumor promoting macrophages. * Participants will take atorvastatin (daily pill) alongside their standard treatment.
Inclusion Criteria: * Be a patient with ovarian cancer aged 18-89 * Diagnosed via tissue biopsy not ascites * For persons of reproductive potential, use of highly effective method(s) of contraception. * Patients with primary Stage III/IV high-grade serous ovarian/fallopian tube/primary peritoneal cancer not amenable to upfront cytoreductive surgery. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2. * Absolute Neutrophil Count 1500 cells/mL * Platelet count \> 100,000 mL. * Hemoglobin 9.0 g/dL * Serum albumin ³ 2.5 g/dL. * Total bilirubin ≤ 1.5 x upper limit of norma…
Neoadjuvant chemotherapy with carboplatin and paclitaxel in addition to daily atorvastatin, interval debulking surgery, then 2-3 additional cycles of carboplatin and paclitaxel
neoadjuvant chemotherapy with 3-4 cycles of carboplatin/paclitaxel, interval debulking surgery, then 2-3 additional cycles of chemotherapy with carboplatin/paclitaxel
Arctuva estimate
Verify or correct the compensation shown for this listing.